Which of the following is not considered a first-line pharmacologic therapy for osteoporosis?

• A. Raloxifene
• B. Bisphosphonates
• C. Denosumab
• D. Zoledronic acid

Answer: (A)

In osteoporosis, the goal of pharmacologic therapy is to lower fracture risk by using agents with strong, proven effects on bone resorption and fracture outcomes. The treatments most commonly used first are antiresorptives that have robust data showing reductions in vertebral, nonvertebral, and hip fractures.

Raloxifene is a selective estrogen receptor modulator that helps preserve bone, and it reduces vertebral fracture risk, but its impact on hip fractures is limited and less consistent. It also carries risks such as venous thromboembolism and hot flashes. Because protecting the hip—and overall fracture risk—takes priority in choosing a first-line therapy, raloxifene is not considered a first-line option for osteoporosis.

In contrast, bisphosphonates (including alendronate, risedronate, ibandronate, and zoledronic acid) and denosumab have strong, broad fracture-reduction data and are regarded as first-line therapies in most guidelines. Zoledronic acid, given yearly, is a potent bisphosphonate, and denosumab provides effective fracture risk reduction as well, with usefulness in patients who cannot tolerate oral bisphosphonates or have renal considerations.

So the drug not considered a first-line osteoporosis therapy is raloxifene.